BACKGROUND:

• CBPP is characterized by immunopathology, i.e. dysregulation of the host’s immune response.

• In vitro data indicates that this dysregulation begins at the very early stages of infection, at the initial site of bacteria-host cell interaction in the

lung.

• We aim towards identifying vaccine candidates that can disrupt the bacteria-induced dysregulation of the host’s immune response.